Gene · 5892
Papers2,681
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 2,681
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients. | Cancer Med | 2023 | 37694493 | PubTator, text mining | PubMed |
| Editorial: Current understanding of genomic and chromosomal instabilities in solid malignancies. | Front Oncol | 2023 | 37692841 | PubTator, text mining | PubMed |
| PALB2 Variants Extend the Mutational Profile of Hungarian Patients with Breast and Ovarian Cancer. | Cancers (Basel) | 2023 | 37686625 | PubTator, text mining | PubMed |
| Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas. | Int J Mol Sci | 2023 | 37686015 | PubTator, text mining | PubMed |
Report on the Effect of the Implementation of an Early Detection and Prevention of Cancer Program on Families at High Hereditary Risk-Concentrating on Patients Undergoing Genetic Diagnostics and Counseling in Central Poland. | Int J Mol Sci | 2023 | 37685988 | PubTator, text mining | PubMed |
| Platinum-based chemotherapy for early triple-negative breast cancer. | Cochrane Database Syst Rev | 2023 | 37681577 | PubTator, text mining | PubMed |
| Hot on RAD51C: structure and functions of RAD51C-XRCC3. | Mol Oncol | 2023 | 37681281 | PubTator, text mining | PubMed |
| Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor. | Hum Pathol | 2023 | 37673346 | PubTator, text mining | PubMed |
| Investigation of germline variants in Bahraini women with breast cancer using next-generation sequencing based-multigene panel. | PLoS One | 2023 | 37656691 | PubTator, text mining | PubMed |
| Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis. | Gynecol Oncol | 2023 | 37651980 | PubTator, text mining | PubMed |
| Finding significance: New perspectives in variant classification of the RAD51 regulators, BRCA2 and beyond. | DNA Repair (Amst) | 2023 | 37651978 | PubTator, text mining | PubMed |
| Mapping the Genetic Interaction Network of PARP inhibitor Response. | bioRxiv | 2023 | 37645833 | PubTator, text mining | PubMed |
| The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer. | Cell Death Dis | 2023 | 37633920 | PubTator, text mining | PubMed |
| Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers. | Int J Mol Sci | 2023 | 37628978 | PubTator, text mining | PubMed |
| Impact of High-to-Moderate Penetrance Genes on Genetic Testing: Looking over Breast Cancer. | Genes (Basel) | 2023 | 37628581 | PubTator, text mining | PubMed |
| The Spectrum of Germline Nucleotide Variants in Gastric Cancer Patients in the Kyrgyz Republic. | Curr Issues Mol Biol | 2023 | 37623222 | PubTator, text mining | PubMed |
| Management of PALB2-associated breast cancer: A literature review and case report. | Clin Case Rep | 2023 | 37621724 | PubTator, text mining | PubMed |
| Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma. | Gynecol Oncol | 2023 | 37611378 | PubTator, text mining | PubMed |
| Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers. | Cancer Med | 2023 | 37610374 | PubTator, text mining | PubMed |
| The dynamic process of covalent and non-covalent PARylation in the maintenance of genome integrity: a focus on PARP inhibitors. | NAR Cancer | 2023 | 37609662 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5892/papers?page=17